Cargando…

Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice

In recent years oral mucosal injury has been increasingly recognized as an important toxicity associated with mammalian target of rapamycin (mTOR) inhibitors, including in patients with breast cancer who are receiving everolimus. This review addresses the state‐of‐the‐science regarding mTOR inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peterson, Douglas E., O'Shaughnessy, Joyce A., Rugo, Hope S., Elad, Sharon, Schubert, Mark M., Viet, Chi T., Campbell‐Baird, Cynthia, Hronek, Jan, Seery, Virginia, Divers, Josephine, Glaspy, John, Schmidt, Brian L., Meiller, Timothy F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971919/ https://www.ncbi.nlm.nih.gov/pubmed/27334013 http://dx.doi.org/10.1002/cam4.761

Ejemplares similares

Recognition and Management of Oral Mucosal Injury Caused by Mammalian Target of Rapamycin Inhibitors: A Case Series
por: Meiller, Timothy F., et al.
Publicado: (2015)

The hedgehog pathway in triple‐negative breast cancer
por: Habib, Joyce G., et al.
Publicado: (2016)

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
por: Tripathy, Debu, et al.
Publicado: (2019)

The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors
por: Phan, Alexandria T., et al.
Publicado: (2016)

A multidisciplinary approach to optimizing care of patients treated with alpelisib
por: Rugo, Hope S., et al.
Publicado: (2021)

Role of tumor microenvironment in the pathobiology of ovarian cancer: Insights and therapeutic opportunities
por: Ghoneum, Alia, et al.
Publicado: (2018)

Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside
por: Basile, Debora, et al.
Publicado: (2019)

New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury
por: Cinausero, Marika, et al.
Publicado: (2017)

Pathobiology
Publicado: (2015)

Pathobiology
Publicado: (2015)

Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2023)

A decade of letrozole: FACE
por: O’Shaughnessy, Joyce
Publicado: (2007)

A decade of letrozole: FACE
por: O’Shaughnessy, Joyce
Publicado: (2008)

Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy
por: O’Shaughnessy, Joyce
Publicado: (2020)

Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice
por: Bitto, Alessandro, et al.
Publicado: (2016)

Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine
por: Levin, Maren K, et al.
Publicado: (2015)

Rheb and mammalian target of rapamycin in mitochondrial homoeostasis
por: Groenewoud, Marlous J., et al.
Publicado: (2013)

Fatty Acid Synthase Impacts the Pathobiology of Candida parapsilosis In Vitro and during Mammalian Infection
por: Nguyen, Long Nam, et al.
Publicado: (2009)

PRINCIPLES OF PATHOBIOLOGY
Publicado: (1976)

PRINCIPLES OF PATHOBIOLOGY
Publicado: (1972)

The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer
por: Tripathy, Debu, et al.
Publicado: (2014)

Inhibition of mammalian target of rapamycin by rapamycin increases the radiosensitivity of esophageal carcinoma Eca109 cells
por: ZHANG, DEJUN, et al.
Publicado: (2014)

Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2011)

SIRT1 Negatively Regulates the Mammalian Target of Rapamycin
por: Ghosh, Hiyaa Singhee, et al.
Publicado: (2010)

Mammalian target of rapamycin signaling in diabetic cardiovascular disease
por: Chong, Zhao Zhong, et al.
Publicado: (2012)

Driving neural regeneration through the mammalian target of rapamycin
por: Maiese, Kenneth
Publicado: (2014)

Therapeutic control of leishmaniasis by inhibitors of the mammalian target of rapamycin
por: Khadir, Fatemeh, et al.
Publicado: (2018)

Autism Spectrum Disorder and Mammalian Target of Rapamycin System
por: Posar, Annio, et al.
Publicado: (2020)

Crosstalk of the Caspase Family and Mammalian Target of Rapamycin Signaling
por: Yan, Junfang, et al.
Publicado: (2021)

Family history of gastric mucosal abnormality and the risk of gastric cancer: a population-based observational study
por: Song, Huan, et al.
Publicado: (2018)

Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
por: Rugo, Hope S., et al.
Publicado: (2020)

Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer
por: Turner, Stuart, et al.
Publicado: (2021)

Combining the mammalian target of rapamycin inhibitor, rapamycin, with resveratrol has a synergistic effect in multiple myeloma
por: Jin, Hong-Guang, et al.
Publicado: (2018)

Rapamycin protects against aristolochic acid nephropathy in mice by potentiating mammalian target of rapamycin-mediated autophagy
por: Lin, Fan, et al.
Publicado: (2021)

Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison
por: Rugo, Hope S., et al.
Publicado: (2023)

Mammalian Tribbles Homologs at the Crossroads of Endoplasmic Reticulum Stress and Mammalian Target of Rapamycin Pathways
por: Cunard, Robyn
Publicado: (2013)

The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs
por: O’Shaughnessy, Megan, et al.
Publicado: (2023)

Pathobiology of Alzheimer's disease /
Publicado: (1995)

Pathobiology of the gastric mucosa.
por: West, A. B., et al.
Publicado: (1996)

Pathobiology of Hodgkin Lymphoma
por: Piccaluga, Pier Paolo, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_jac2qffi457nr58gcqah3nnuip